Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Importance The optimal duration of dual antiplatelet therapy (DAPT) for older adults after
percutaneous coronary intervention (PCI) is uncertain because they are simultaneously at …

Background Although dual antiplatelet therapy (DAPT) improves the outcomes of patients
undergoing percutaneous coronary intervention (PCI), sex-specific differences in efficacy …

Background Patients treated with drug-coated balloons (DCB) have the theoretical
advantage of adopting a low-intensity antiplatelet regimen due to the absence of struts and …

Importance P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12
inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for …

Introduction Over the course of 2021, numerous key clinical trials with valuable contributions
to clinical cardiology were published or presented at major international conferences. This …

Background and aims High bleeding risk (HBR) and acute coronary syndrome (ACS)
subtypes are critical in determining bleeding and cardiovascular event risk after …

Abstract Purpose of Review Optimal duration of antiplatelet therapy continues to attract
extensive debates and has been progressively adjusted in the setting of advancements in …

Dual antiplatelet therapy—the combination of aspirin and a P2Y12 inhibitor—remains the
standard antiplatelet regimen recommended to prevent ischemic complications immediately …

BACKGROUND: The efficacy and safety of each third-generation drug-eluting stent with
ultrathin struts and advanced polymer technology remain unclear. We investigated the …